back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2020-12-28 16:58 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
$498,294 | |
| Filed 2020-12-28 16:57 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
| Filed 2020-12-28 16:25 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$3,948 vol $12.03 each |
||
| Filed 2020-12-28 16:24 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
40,000 | |
| Filed 2020-12-28 16:23 Tx date 2017-09-13 |
$TRIL
Trillium Therapeutics Inc. |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-01-02 16:52 Tx date 2019-12-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$14,792 vol $1.16 each |
$494,346 | |
| Filed 2019-11-11 14:57 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$348,333 vol $0.36 each |
$479,554 | |
| Filed 2019-10-02 15:33 Tx date 2019-09-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$39,154 vol $0.4467 each |
$131,221 | |
| Filed 2019-07-03 14:06 Tx date 2019-06-30 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$41,425 vol $0.4358 each |
$92,067 | |
| Filed 2019-04-05 10:14 Tx date 2019-03-31 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$19,614 vol $0.92 each |
$50,642 | |
| Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$29,181 vol $4.26 each |
$31,028 | |
| Filed 2017-11-14 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
97 - Other
|
$
+$1,847 vol $12.18 each |
$1,847 | |
| Filed 2017-11-14 Tx date 2017-09-13 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Tayton-Martin, Helen Katrina
4 - Director of Issuer
Direct Ownership
|
Deferred share units
00 - Opening Balance-Initial SEDI Report
|